Biodegradable polymer support containing bioactive material and manufacturing method therefor
US-2024299626-A1 · Sep 12, 2024 · US
US10004834B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10004834-B2 |
| Application number | US-201414484943-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 12, 2014 |
| Priority date | Sep 13, 2013 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A braided polymeric scaffold, made at least in part from a bioresorbable material is deployed on a catheter that uses a push-pull mechanism to deploy the scaffold. A drug coating is disposed on the scaffold. A plurality of scaffold segments on a catheter is also disclosed.
Opening claim text (preview).
What is claimed is: 1. A self-expanding stent for treating a peripheral vessel, comprising: a segmented braided scaffold including a plurality of braided scaffold segments configured to be deployed end to end in a vessel, and at least three of the braided scaffold segments are hybrid segments, each of which comprising non-degradable filaments and degradable filaments woven to form a tubular configuration, wherein upon deployment of the scaffold from a collapsed state to a deployed state in a body cavity, the degradable filaments degrade and a radial strength or stiffness of the hybrid segments decreases with time, wherein when the degradable filaments are completely degraded, each hybrid segment comprises a residual stiffness provided by the non-degradable filaments, and wherein a hybrid proximal end segment a hybrid distal end segment of the scaffold have a higher radial strength or stiffness at deployment than a middle hybrid segment thereof, while having the same residual radial strength or stiffness as the middle hybrid segment, and wherein a first degradable polymer filament of the proximal and distal hybrid end segments has a higher degradation rate than a second degradable polymer filament of the middle hybrid segment so that a rate of decrease to the residual strength or stiffness is faster for the proximal and distal hybrid end segments than the middle hybrid segment. 2. The stent of claim 1 , wherein the non-degradable filaments are nitinol. 3. The stent of claim 1 , wherein the degradable filaments comprise a polymer selected from the group consisting of poly(L-lactide), poly(L-lactide-co-glycolide), poly(DL-lactide), and polyglycolide. 4. The stent of claim 1 , wherein the degradable filaments comprise a bioabsorbable polymer. 5. The stent of claim 1 , wherein the radial strength or stiffness of at least one of the hybrid end segments decreases by no greater than 60% during the first 3 months after deployment. 6. The stent of claim 1 , wherein the radial strength or stiffness of at least one of the proximal and distal hybrid end segments decreases by at least about 50% during the first 3 months after deployment. 7. The stent of claim 1 , wherein the stiffness of at least one of the proximal and distal hybrid end segments decreases to 40 to 60% of a stiffness at deployment during the first 3 months after deployment. 8. The stent of claim 1 , wherein the stiffness of at least one of the proximal and distal hybrid end segments decreases to a residual stiffness that is less by 40% to 60% of a deployed stiffness, by at least 3 months after deployment. 9. The stent of claim 1 , wherein a combined length of the distal and proximal hybrid end segments are 10% to 30% of a total length of the scaffold. 10. The stent of claim 1 , wherein one of the hybrid proximal end segment and hybrid distal end segment comprises a metal filament having a cross sectional area (Am), and a degradable filament having a cross-sectional area (Ap), wherein the ratio Ap/Am is 2 to 4. 11. The stent of claim 1 , wherein one of the hybrid proximal end segment and hybrid distal end segment comprises a number of metal filaments (Nm) and a number of polymer filaments (Np), wherein the ratio Np/Nm is 2 to 10.
differing in diameter · CPC title
Materials at least partially resorbable by the body · CPC title
differing in elasticity, stiffness or compressibility · CPC title
characterised by a net-like or mesh-like structure · CPC title
containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.